- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01584726
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma
January 27, 2014 updated by: Hamad Medical Corporation
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)
The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.
Study Overview
Detailed Description
the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency
follow asthma severity score and length of stay
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dr. Khalid Al Ansari, MD,FRCP,FAAP
- Phone Number: 6006 97444396001
- Email: dkmaa@hotmail.com
Study Contact Backup
- Name: Dr. Wessam Mouharam, MD
- Phone Number: 6012 97444396022
- Email: wessam_mouharam@yahoo.com
Study Locations
-
-
-
Doha, Qatar, 3050
- Recruiting
- Hamad Medical Corporation
-
Contact:
- KHALID AL ANSARI, MD,FRCP,FAAP
- Phone Number: 6001 +974 44396006
- Email: dkmaa@hotmail.com
-
Contact:
- WESSAM MOUHARAM, MD
- Phone Number: 6012 +97444396022
- Email: wessam_mouharam@yahoo.com
-
Principal Investigator:
- Dr,KHALID AL ANSARI, MD,FRCP,FAAP
-
Sub-Investigator:
- WESSAM MOUHARAM, MD
-
Doha, Qatar, 3050
- Recruiting
- Pediatric Emergency Centre
-
Sub-Investigator:
- WESSAM MOUHARAM, MD
-
Contact:
- KHALID AL ANSARI, MD,FRCP,FAAP
- Phone Number: 6006 97444396022
- Email: dkmaa@hotmail.com
-
Contact:
- WESSAM MOUHARAM, MD
- Phone Number: 6012 9744396022
- Email: wessam_mouharam@yahoo.com
-
Principal Investigator:
- KHALID AL ANSARI, MD,FRCP,FAAP
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pediatric asthma patients with moderate to severe exacerbation
Exclusion Criteria:
- Known allergy to magnesium sulfate
- History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease
- Use of oral steroid medication within 72 hours of presentation
- Radiographic evidence of pneumonia at presentation
- Administration of intravenous magnesium sulfate prior to study enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: magnesium sulfate arm
magnesium sulfate with standard therapy
|
single dose of magnesium sulfate nebulization
|
No Intervention: placebo arm
placebo with standard therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge?
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease admission and readmission rate, compared to placebo
Time Frame: 36 months
|
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: KHALID AL ANSARI, MD, SENIOR CONSULTANT-HEAD OF PEDIATRIC EMERGENCY
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Anticipated)
March 1, 2015
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
April 17, 2012
First Submitted That Met QC Criteria
April 24, 2012
First Posted (Estimate)
April 25, 2012
Study Record Updates
Last Update Posted (Estimate)
January 28, 2014
Last Update Submitted That Met QC Criteria
January 27, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Magnesium Sulfate
Other Study ID Numbers
- #12095/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Magnesium Sulfate
-
Aurora Health CareNot yet recruitingAtrial Fibrillation | Tachycardia Atrial | Atrial Flutter With Rapid Ventricular ResponseUnited States
-
University of OklahomaRecruitingAsthma in Children | Asthma AttackUnited States
-
Sohag UniversityRecruitingPost Operative Pain, AcuteEgypt
-
Thomas Jefferson UniversityNot yet recruiting
-
Queen Sirikit National Institute of Child HealthUnknownAcute Severe AsthmaThailand
-
Sohag UniversityCompletedPersistent Pulmonary Hypertension of the Newborn | PPHN | Persistent Fetal CirculationEgypt
-
Instituto Materno Infantil Prof. Fernando FigueiraCompletedSevere PreeclampsiaBrazil
-
Assiut UniversityCompletedMaternal Care PatternsEgypt
-
Assiut UniversityRecruitingIntracranial Pressure Control in Pre-eclampsiaEgypt
-
University of Texas Southwestern Medical CenterCompletedAsthmaUnited States